Paul Larson

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

William J. Marks, Raymond T. Bartus, João Siffert et al. · The Lancet Neurology · 2010 · 669 citations

Neurodegenerative Diseases, Neurology, Gene Delivery +4

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

William J. Marks, Jill L. Ostrem, L. Verhagen et al. · The Lancet Neurology · 2008 · 581 citations

Neurodegenerative Diseases, Idiopathic Parkinson, Medicine +4

Safety and tolerability of putaminal <i>AADC</i> gene therapy for Parkinson disease

Chadwick W. Christine, Philip A. Starr, Paul Larson et al. · Neurology · 2009 · 424 citations · Full text

Results from a phase I safety trial of <i>hAADC</i> gene therapy for Parkinson disease

Jamie L. Eberling, William J. Jagust, Chadwick W. Christine et al. · Neurology · 2008 · 364 citations

Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson’s disease

Ro’ee Gilron, Simon Little, Randy Perrone et al. · Nature Biotechnology · 2021 · 330 citations · Full text

Neurophysiology, Adaptive Stimulation, Circuit Neuroscience +14